{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:31:23Z","timestamp":1772253083033,"version":"3.50.1"},"reference-count":20,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: In spite of compelling evidence demonstrating safety and immunogenicity of adenoviral-based SARS-CoV-2 vaccines in the general population, its effects in socially vulnerable elderly individuals are poorly understood. Here we aimed to investigate the efficacy of two doses of combined vector vaccine, the Gam-COVID-Vac (Sputnik-V vaccine), at 14, 42, and 180 days after immunization, in a nursing home for underprivileged population and homeless individuals. Methods: A phase 3, open-label clinical trial involving administration of two adenoviral vectors (Ad26-Ad5) vaccine, in elderly individuals over the ages of 60 years was performed. SARS-CoV-2 Spike RBD-specific IgG antibodies at days 21-, 42- and 180 post-vaccination was analyzed in sera of individuals receiving two doses of the Sputnik-V vaccine with an interval of 21 days. SARS-CoV-2-specific CD8+ T cell responses, measured by intracellular tumor necrosis factor (TNF) was determined by flow cytometry following antigen-specific cultures. Results: A total of 72 elderly adults with a mean age of 72.6 \u00b1 9.5 years-old was selected after applying the inclusion criteria, all corresponding to an underprivileged population. Two-doses vaccination with Sputnik-V vaccine elicited an antibody-mediated immune response (revealed by quantitative detection of SARS-CoV-2-specific IgG antibodies, CMIA) 70% at day 21, 90% at day 42, and 66.1% at day 180. Fully vaccinated individuals had robust SARS-CoV-2-specific T cell responses, evidenced by TNF production in CD4+ and CD8+ T cells in all time periods analyzed. Conclusion: Six months after receipt of the second dose of the Gam-COVID-Vac vaccine, SARS-CoV-2-specific IgG levels declined substantially among the tested population, whereas CD4+ and CD8+ T-cell-mediated immunity remained at high levels. These data suggest that two doses of combined adenoviral-based vaccine elicits a considerable level of SARS-CoV-2 immune responses in elderly individuals, highlighting its safety and immunogenicity in this highly vulnerable population.<\/jats:p>","DOI":"10.3390\/vaccines10060937","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T06:31:59Z","timestamp":1655101919000},"page":"937","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody- and T Cell-Dependent Responses Elicited by a SARS-CoV-2 Adenoviral-Based Vaccine in a Socially Vulnerable Cohort of Elderly Individuals"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-8169","authenticated-orcid":false,"given":"Martin","family":"Moya","sequence":"first","affiliation":[{"name":"City Council of Cordoba, 5000 Cordoba, Argentina"},{"name":"Facultad de Ciencias M\u00e9dicas, Universidad Nacional de C\u00f3rdoba, 5000 Cordoba, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela","family":"Marrama","sequence":"additional","affiliation":[{"name":"City Council of Cordoba, 5000 Cordoba, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5814-3969","authenticated-orcid":false,"given":"Carina","family":"Dorazio","sequence":"additional","affiliation":[{"name":"City Council of Cordoba, 5000 Cordoba, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florencia","family":"Veigas","sequence":"additional","affiliation":[{"name":"Laboratorio de Glicomedicina, Instituto de Biolog\u00eda y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), C1428 Ciudad de Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-6258","authenticated-orcid":false,"given":"Montana N.","family":"Manselle Cocco","sequence":"additional","affiliation":[{"name":"Laboratorio de Glicomedicina, Instituto de Biolog\u00eda y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), C1428 Ciudad de Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Dalotto Moreno","sequence":"additional","affiliation":[{"name":"Laboratorio de Glicomedicina, Instituto de Biolog\u00eda y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), C1428 Ciudad de Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel A.","family":"Rabinovich","sequence":"additional","affiliation":[{"name":"Laboratorio de Glicomedicina, Instituto de Biolog\u00eda y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), C1428 Ciudad de Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Aleksandroff","sequence":"additional","affiliation":[{"name":"City Council of Cordoba, 5000 Cordoba, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe COVID-19","volume":"384","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(20)30633-4","article-title":"Clinical course and mortality risk of severe COVID-19","volume":"395","author":"Weiss","year":"2020","journal-title":"Lancet"},{"key":"ref_5","unstructured":"(2022, March 08). WHO Coronavirus Disease (COVID-2019) Situation Reports. Available online: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/cid\/ciaa310","article-title":"Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)","volume":"71","author":"Guo","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41586-021-04120-y","article-title":"Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination","volume":"600","author":"Pozzetto","year":"2021","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"ref_10","first-page":"683","article-title":"COVID-T: A functionalplatformto monitor SARS-CoV-2-specific T cell responses in vaccinatedindividuals and COVID-19 recoveredpatients","volume":"81","author":"ManselleCocco","year":"2021","journal-title":"Medicina (Buenos Aires)"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study","volume":"6","author":"Naaber","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJMc070348","article-title":"Disappearance of antibodies to SARS-associated coronavirus after recovery","volume":"357","author":"Cao","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.vaccine.2016.02.063","article-title":"Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection","volume":"34","author":"Ng","year":"2016","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Goel, R.R., Painter, M.M., Apostolidis, S.A., Mathew, D., Meng, W., Rosenfeld, A.M., Lundgreen, K.A., Reynaldi, A., Khoury, D.S., and Pattekar, A. (2021). mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern. bioRxiv.","DOI":"10.1101\/2021.08.23.457229"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-021-03647-4","article-title":"SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans","volume":"595","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15729","DOI":"10.1038\/s41598-021-95025-3","article-title":"Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains","volume":"11","author":"Rella","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/6\/937\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:28:33Z","timestamp":1760138913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/6\/937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["vaccines10060937"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10060937","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1538891\/v1","asserted-by":"object"}]},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]}}}